<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 73-year-old man was given a diagnosis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> in October 1997 </plain></SENT>
<SENT sid="1" pm="."><plain>He was treated with red blood cell transfusion and granulocyte-colony stimulating factor (G-CSF) </plain></SENT>
<SENT sid="2" pm="."><plain>In February 1998, he was admitted due to progression of <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Bone marrow <z:hpo ids='HP_0002835'>aspiration</z:hpo> revealed <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation </plain></SENT>
<SENT sid="4" pm="."><plain>The patient was treated with continuous-drip infusion of low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and <z:chebi fb="0" ids="4911">etoposide</z:chebi> with G-CSF (AVG therapy) </plain></SENT>
<SENT sid="5" pm="."><plain>Complete remission (CR) was obtained after 2 courses of AVG therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Non-hematologic adverse effects were mild enough to be tolerated </plain></SENT>
<SENT sid="7" pm="."><plain>CR has been maintained for 16 months with 1 course of consolidation therapy and 3 courses of intensification therapy using the AVG regimen </plain></SENT>
</text></document>